ClinicalTrials.gg
CompletedNCT04291781Updated Sep 19, 2024

A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy

A Phase 2 interventional study of RC18 160mg and RC18 240mg in Primary IgA Nephropathy, sponsored by RemeGen Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by RemeGen Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Enrollment
71st of 109
44 · median 84
Started
2020
with 6 others
Phase 2
27 of 127
14 open now
Registered
32nd of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 71st largest by enrollment of the 109 interventional ones that give a count, is one of 7 that started in 2020, is one of 27 in phase 2, and was the 32nd registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of Tai Ai(Recombinant Human B Lymphocyte Stimulator Receptor-Antibody Fusion Protein for Injection) in the treatment of IgA nephropathy.

Read the detailed description

Both RC18 and Recombinant Human B Lymphocyte Stimulator Receptor-Antibody Fusion Protein for Injection are other names of Tai Ai.

After a 35-day screen period, subjects are randomly allocated into 3 groups receiving subcutaneous injection of Tai Ai 160mg, Tai Ai 240mg, and placebo once a week individually. The treatment lasts 24 weeks. Subjects, the sponsor, investigators are blinded in the whole process of the trial.

03

Conditions studied

  • Primary IgA Nephropathy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signing the ;
  2. confirmed diagnosis of IgA nephropathy;
  3. Male or female, between 18 and 70 years age;
  4. During screening, 24-hour urine protein excretion ≥0.75 g/24h at Visit 1 and/or Visit 2 and at Visit 3;
  5. Estimated (eGFR) (CKD-EPI ) >35 ml/min per 1.73m\^2;
  6. Have received the Angiotension converting enzyme Inhibitors(ACEI)/Angiotensin receptor blocker(ARB) standard treatment for 12 weeks prior to randomization, and have stabled the dosage (within the maximum tolerated dosage) for 4 weeks prior to randomization.

Exclusion criteria

Exclusion Criteria:

  1. Abnormal laboratory tests;
  2. Any secondary IgA nephropathy caused by Henoch-Schönlein purpura, ankylosing spondylitis, systemic lupus erythematosus, sjogren syndrome, viral hepatitis, liver cirrhosis, rheumatoid arthritis, mixed connective tissue disease, polyarteritis nodosa, erythema nodosum, psoriasis, ulcerative colitis, crohn\'s disease, tumor, AIDS ,etc.;
  3. Any nephropathy with special pathologic or clinical types, such as nephrotic syndrome, crescentic glomerulonephritis(with >50% of biopsied glomeruli), minimal change disease with IgA deposition; and IgA nephropathy requiring treatment.
  4. Suffering from cardiovascular and cerebrovascular events (myocardial infarction, unstable angina, ventricular arrhythmia, grade III-IV heart failure, stroke, etc.) within the last 12 weeks;
  5. Treating with systemic corticosteroids drug(excluding topical or nasal steroids) within 3 months prior to randomizing;
  6. Treating with systemic immunosuppressor within 3 months prior to randomizing: cyclophosphamide, azathioprine, mycophenolate mofetil, leflunomide, tacrolimus, cyclosporine, rituximab, tripterygium wilfordii, etc.;
  7. Requiring hospitalization or intravenous antibiotics treatment due to active infection within 3 months prior to randomizing;
  8. Active tuberculosis or latent carrier without treatment;
  9. Herpes zoster infected patients or patients with positive antibody or positive antibody;
  10. Active hepatitis or severe liver disease, and infection (According to the HBV screening test, ① the HBsAg-positive; ②HBsAg-negative and HBcAb-positive, the HBV-DNA should be tested to determine the situation: the HBV-DNA positive subjects should be excluded, while the HBV-DNA negative subjects can participated in.)
  11. With malignant tumors;
  12. Pregnancy ,lactation, or patients with childbearing plans during the trial;
  13. Nephrotoxic drugs is unavoidable during the study period;
  14. Allergy to human-derived biologics;
  15. Receiving any other investigating drug 4 weeks or 5 times half-life of the experimental drug (whichever is longer) prior to randomization;
  16. Not suitable for the study judged by investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    RC18 160mg

    RC18 160mg subcutaneous injection (S.C.) once weekly ,and a total of 24 doses

    Biological: RC18 160mg

  • Experimental
    RC18 240mg

    RC18 240mg S.C. once weekly ,and a total of 24 doses

    Biological: RC18 240mg

  • Placebo comparator
    Placebo

    Placebo S.C. once weekly ,and a total of 24 doses

    Biological: placebo

Interventions

  • BiologicalRC18 160mg

    subcutaneous injection on the upper arm, abdomen, or upper thigh outside;

    Also known as: Tai Ai, Recombinant Human B-Lymphocyte Stimulator Receptor- Antibody Fusion Protein

  • BiologicalRC18 240mg

    subcutaneous injection on the upper arm, abdomen, or upper thigh outside;

    Also known as: Tai Ai, Recombinant Human B-Lymphocyte Stimulator Receptor- Antibody Fusion Protein

  • Biologicalplacebo

    subcutaneous injection on the upper arm, abdomen, or upper thigh outside;

06

What researchers measure

Primary outcomes

  1. Change from baseline in 24-hour urine protein excretion at Week 24;

    based on the 24 -hour urine collection

    Time frame: week 24

Secondary outcomes

  1. Change from baseline in estimated Glomerular Filtration Rate(eGFR)

    eGFR is calculated using the CKD-EPI method.

    Time frame: week 0, 4, 8, 12, 16, 20, 24

  2. Change from baseline in urine protein/creatine ratio(UPCR) and/or urine albumin/ creatine ratio(UACR)

    Time frame: week 0, 4, 8, 12, 16, 20, 24

  3. Change from baseline in Immunoglobulin G(IgG);

    Time frame: week 0, 4, 8, 12, 16, 20, 24

  4. Change from baseline in Immunoglobulin M(IgM);

    Time frame: week 0, 4, 8, 12, 16, 20, 24

  5. Change from baseline in Immunoglobulin A(IgA);

    Time frame: week 0, 4, 8, 12, 16, 20, 24

  6. Change from baseline in the count of urine red blood cells

    Time frame: week 0, 4, 8, 12, 16, 20, 24

  7. Change from baseline in the count of B-lymphocytes (CD19+)

    Time frame: week 0, 4, 8, 12, 16, 20, 24

  8. Change from baseline in complement 3(C3)

    Time frame: week 0, 4, 8, 12, 16, 20, 24

  9. Change from baseline in complement 4 (C4)

    Time frame: week 0, 4, 8, 12, 16, 20, 24

  10. The incidence rate and severity of adverse events.

    An adverse event is any undesirable experience associated with the use of a medical product in a patient.

    Time frame: week 0, 4, 8, 12, 16, 20, 24

07

Study locations

1 site
  • Peking University First Hospital.
    Beijing, Beijing 100010, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in May 2021, 13 months.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2020
First posted
Mar 2, 2020
StartActual
Apr 13, 2020
Primary completionActual
May 20, 2021
CompletionActual
May 20, 2021
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04291781
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Mar 2, 2020
Start date
Apr 13, 2020
Primary completion
May 20, 2021
Completion
May 20, 2021
Last update
Sep 19, 2024

Study contacts

Hong Zhang, M.D.
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion